Shares of Canopy Growth Corp (TSE:WEED – Get Free Report) were up 12.7% during mid-day trading on Monday . The stock traded as high as C$7.77 and last traded at C$7.65. Approximately 1,752,120 shares traded hands during trading, a decline of 16% from the average daily volume of 2,082,528 shares. The stock had previously closed at C$6.79.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group reduced their target price on Canopy Growth from C$5.00 to C$3.50 and set a “sell” rating for the company in a report on Monday, August 12th.
Get Our Latest Research Report on Canopy Growth
Canopy Growth Price Performance
Insider Buying and Selling
In related news, Director David Eric Klein sold 40,135 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of C$8.35, for a total transaction of C$335,303.84. In other Canopy Growth news, Director David Eric Klein sold 40,135 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of C$8.35, for a total transaction of C$335,303.84. Also, Senior Officer Christelle Gedeon sold 16,788 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of C$8.35, for a total value of C$140,253.67. Corporate insiders own 0.21% of the company’s stock.
Canopy Growth Company Profile
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names.
See Also
- Five stocks we like better than Canopy Growth
- Insider Buying Explained: What Investors Need to Know
- Intel: Is Now the Time to Be Brave?Â
- Insider Trades May Not Tell You What You Think
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Best Aerospace Stocks Investing
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.